The U.S. Food and Drug Administration (FDA) has approved the first-ever twice-yearly injectable medication to prevent HIV. Branded Yeztugo® (lenacapavir) and developed by Gilead Sciences,
Multi-omic microsampling analyzes biomarkers in tiny blood samples, enabling personalized tracking of health changes linked to lifestyle factors.
A revolutionary ingestible pill can remotely monitor vital signs like heart rate in real time. Human trials are planned for this futuristic capsule.
The FDA approved the first two gene therapies, Casgevy and Lyfgenia, to treat sickle cell disease. These one-time treatments come with a hefty price tag.
Be the first to be notified by dropping your name and your active email address.
